3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
18
Terminated
7
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Hematologic Neoplasms
5
Myelodysplastic Syndromes
4
Tuberous Sclerosis
2
Recurrence
2
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Epilepsy
2
Bronchiolitis Obliterans Syndrome
2
Thyroid Neoplasms
1
Solid Tumor
1
Sarcoma
1
Prostate Cancer Recurrent
1
Non-Malignant Neoplasm
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphangioleiomyomatosis
1
Leukemia, Prolymphocytic
1
Leukemia, Plasma Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid
1
Interventions
Cyclophosphamide
13
pembrolizumab
8
Brentuximab Vedotin
8
fludarabine
7
Nivolumab
7
Whole-Body Irradiation
6
Specimen Handling
6
Mycophenolic Acid
6
Gemcitabine
6
Etoposide
6
Doxorubicin
6
Dacarbazine
6
fludarabine phosphate
5
Vinblastine
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
Dexamethasone
5
Stem Cell Transplantation
4
Cytarabine
4
Vinorelbine
3
Tacrolimus
3
Magnetic Resonance Spectroscopy
3
Cyclosporine
3
Carmustine
3
Blood Specimen Collection
3
thymoglobulin
2
polatuzumab vedotin
2
pegylated granulocyte colony-stimulating factor
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hodgkin Disease
×
Sirolimus
×
Clear all
NCT04888741
2026-05-05
MoTD
University of Birmingham
Phase 2
Recruiting
400 enrolled